Key takeaways

  • IHE offers lower costs and higher income through a concentrated play on established drugmakers, while IBB provides broader exposure to 243 biotech firms with higher volatility.
  • Since 2021, IHE has generated a total return of 79%, equating to a compound annual growth rate (CAGR) of 12.4%.
  • IHE is more affordable with an expense ratio of 0.44%, while IBB's is 0.37%.

The iShares U.S. Pharmaceuticals ETF offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF. The iShares Biotechnology ETF provides exposure to a broader group of 243 companies, while the iShares U.S. Pharmaceuticals ETF is concentrated in only 53 holdings.

See the latest quote, chart and news for IHE.

Read the full story at fool.com ↗